We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00382044
Recruitment Status : Completed
First Posted : September 28, 2006
Last Update Posted : May 23, 2008
Information provided by:
Sir Charles Gairdner Hospital

Brief Summary:
The purpose of this study is to audit the effects of changing all hemodialysis patients from intravenous to subcutaneous administration of ESA's, to ensure that a cost-saving is achieved and that this does not occur at the expense of anemia control. The dose changes will occur according to usual clinical care of patients and not along a protocol.

Condition or disease Intervention/treatment
Kidney Failure, Chronic Anemia Drug: Eprex; Neorecormon; Aranesp

  Show Detailed Description

Study Type : Observational
Estimated Enrollment : 150 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Audit of the Effect of Changing From IV to SC Administration of Erythropoiesis Stimulating Agents in Haemodialysis Patients - Real Life Clinical Experience
Study Start Date : September 2006
Primary Completion Date : December 2007
Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • On haemodialysis at a Sir Charles Gairdner Hospital Unit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00382044

Australia, Western Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia, 6009
Sponsors and Collaborators
Sir Charles Gairdner Hospital
Study Director: Neil C Boudville, MBBS Sir Charles Gairdner Hospital

Responsible Party: Dr Neil Boudville, Sir Charles Gairdner Hospital
ClinicalTrials.gov Identifier: NCT00382044     History of Changes
Other Study ID Numbers: NB-06-10
First Posted: September 28, 2006    Key Record Dates
Last Update Posted: May 23, 2008
Last Verified: May 2008

Keywords provided by Sir Charles Gairdner Hospital:
Kidney Failure, Chronic

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Darbepoetin alfa